Stock Market Today, March 16: CytomX Therapeutics Surges After Positive Phase 1 Colorectal Cancer Data

CytomX Therapeutics (NASDAQ:CTMX), a biotech company that develops conditionally activated biologics for cancer treatment, closed Monday at $6.75, up 44.23%. The stock is jumping after releasing Phase 1 Varseta-M data in metastatic colorectal cancer and subsequent upbeat analyst reactions. Investors will now be watching upcoming FDA interactions and further clinical readouts.Trading volume reached 118 million shares, coming in about 2,211% above its three-month average of 5.1 million shares. CytomX IPO'd in ...